Related Experiment Video

Updated: Jul 8, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

Type 2 diabetes and oral antihyperglycemic drugs

Cassia S Mizuno1, Amar G Chittiboyina, Theodore W Kurtz

  • 1Department of Medicinal Chemistry, School of Pharmacy, University of Mississippi, University, MS 38677-1848, USA.

Current Medicinal Chemistry
|January 29, 2008
PubMed

Insights

Type II diabetes poses a global health challenge due to its complex nature and costly complications. This review examines current oral hypoglycemic drugs, highlighting their pros and cons, and explores emerging treatments for better diabetes management.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Public Health

Background:

  • Type II diabetes is a complex, multifactorial disease with significant global health and economic impacts.
  • Current oral hypoglycemic agents have limitations regarding safety and efficacy.
  • Developing novel therapeutic strategies is crucial for effective diabetes management.

Purpose of the Study:

  • To provide a comprehensive overview of existing oral hypoglycemic drug classes for Type II diabetes.
  • To critically evaluate the advantages and disadvantages of each drug class.
  • To discuss recent advancements and future directions in Type II diabetes drug development.

Main Methods:

  • Literature review of established and emerging oral hypoglycemic agents.
  • Comparative analysis of safety and efficacy profiles of different drug classes.
  • Synthesis of current research on novel therapeutic targets and drug candidates.

Main Results:

  • Detailed pros and cons of sulfonylureas, biguanides, alpha-glucosidase inhibitors, meglitinides, DPP-4 inhibitors, and thiazolidinediones.
  • Identification of unmet needs and challenges in current Type II diabetes pharmacotherapy.
  • Overview of promising new drug classes and therapeutic approaches.

Conclusions:

  • No single oral hypoglycemic drug offers a perfect balance of safety and efficacy for all Type II diabetes patients.
  • A thorough understanding of existing drug classes is essential for optimal patient care.
  • Ongoing research into novel therapeutic agents holds promise for improved Type II diabetes treatment outcomes.

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...